- Clinical Trials
- April 2024
- 60 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- July 2022
- 173 Pages
Global
From €1909EUR$2,000USD£1,599GBP
The Acinetobacter Infection Drug market is a subset of the larger Infectious Diseases Drugs market. It is composed of drugs used to treat infections caused by Acinetobacter bacteria, which are Gram-negative bacteria that can cause a range of infections, from pneumonia to meningitis. These drugs are typically antibiotics, such as carbapenems, aminoglycosides, and fluoroquinolones, and are used to treat severe infections. The Acinetobacter Infection Drug market is highly competitive, with many companies developing and marketing drugs to treat Acinetobacter infections.
Some companies in the Acinetobacter Infection Drug market include Merck & Co., Pfizer, GlaxoSmithKline, AstraZeneca, Sanofi, and Novartis. Show Less Read more